Department of General Surgery, The Second Hospital Affiliated to Jiaxing University, Jiaxing, Zhejiang, China (mainland).
Med Sci Monit. 2018 Dec 11;24:8964-8969. doi: 10.12659/MSM.911914.
BACKGROUND The aim of this study was to explore the risk factors for post-endoscopic retrograde cholangiopancreatography (ERCP) pancreatitis and investigate the effect of octreotide combined with nonsteroidal anti-inflammatory drugs on preventing its occurrence. MATERIAL AND METHODS A total of 139 patients undergoing ERCP in our hospital from May 2016 to April 2017 were retrospectively analyzed, and divided into an observation group (n=67) (octreotide + indomethacin) and a control group (n=72) (no preventive drugs). The preoperative and postoperative inflammatory cytokines such as tumor necrosis factor-α (TNF)-α, interleukin-6 (IL-6) and IL-8, and serum amylase levels were measured, and the incidence of pancreatitis and hyper amylasemia were monitored. RESULTS Serum amylase level was increased significantly 3 hours after operation in both groups with significantly higher level in the control group compared to the observation group. After 24 hours, serum amylase in the observation group was decreased to preoperative level, whereas it was still higher than preoperative in the control group (P<0.05). Regarding the levels of TNF-α, IL-6, IL-8, and visual analogue scale, they were significantly increased in both groups after operation with significantly higher levels in the control group compared to the observation group (P<0.05). Furthermore, logistic regression analysis showed that difficult intubation, pancreatic duct angiography, surgery for a long time, and the history of previous pancreatitis were risk factors for post-ERCP pancreatitis (P<0.05). CONCLUSIONS Difficult intubation, pancreatic duct angiography, surgery for a long time, and the history of previous pancreatitis were risk factors for post-ERCP pancreatitis. Octreotide combined with non-steroidal anti-inflammatory drugs can reduce the pain of patients with abdominal pain as well as the incidence of postoperative pancreatitis, indicating that they might be effective preventative approaches for pancreatitis.
本研究旨在探讨内镜逆行胰胆管造影(ERCP)后胰腺炎的危险因素,并探讨奥曲肽联合非甾体抗炎药预防其发生的效果。
回顾性分析我院 2016 年 5 月至 2017 年 4 月行 ERCP 的 139 例患者,分为观察组(n=67)(奥曲肽+吲哚美辛)和对照组(n=72)(无预防药物)。检测术前和术后肿瘤坏死因子-α(TNF)-α、白细胞介素-6(IL-6)、白细胞介素-8(IL-8)等炎症细胞因子和血清淀粉酶水平,并监测胰腺炎和高淀粉酶血症的发生率。
两组术后 3 小时血清淀粉酶水平明显升高,对照组明显高于观察组。术后 24 小时观察组血清淀粉酶降至术前水平,对照组仍高于术前(P<0.05)。TNF-α、IL-6、IL-8 水平和视觉模拟评分(VAS)两组术后均明显升高,对照组明显高于观察组(P<0.05)。Logistic 回归分析显示,插管困难、胰管造影、手术时间长、既往胰腺炎史是 ERCP 后胰腺炎的危险因素(P<0.05)。
插管困难、胰管造影、手术时间长、既往胰腺炎史是 ERCP 后胰腺炎的危险因素。奥曲肽联合非甾体抗炎药可减轻患者腹痛程度和术后胰腺炎发生率,表明其可能是预防胰腺炎的有效方法。